Agranulocytosis after long-term clozapine use: a case report

Neutropenia and the more severe, potentially life-threatening agranulocytosis are recognized side effects of clozapine that require regular, mandatory, and life-long blood monitoring. However, most cases of haematological adverse effects occur in the first few months of treatment; therefore, there are now increasing calls for the termination of the mandatory monitoring after this initial period. In this report, we present a patient with treatment-resistant schizophrenia who was successfully treated with clozapine yet developed neutropenia after 9 years. This soon evolved into agranulocytosis requiring the use of granulocyte colony-stimulating factor and eventual clozapine cessation. Such late-onset cases of agranulocytosis are isolated and rare but should not impede the drive to relax mandatory clozapine haematological monitoring, but patients and carers must be aware of potential symptoms of agranulocytosis.

Authors

Institutions

Publication Details

Journal
International Clinical Psychopharmacology
Published
2025-05-27
DOI
https://doi.org/10.1097/yic.0000000000000594
Citations
1
Primary Topic
Blood disorders and treatments
Type
article
Field-Weighted Citation Impact
1.82
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Agranulocytosis after long-term clozapine use: a case report

Agostina Secchi, Sukhwinder S. Shergill, Eromona Whiskey, Madelaine Bridges
1 citations
International Clinical Psychopharmacology
Blood disorders and treatments
1.82
article

Agranulocytosis after long-term clozapine use: a case report

Agostina Secchi, Sukhwinder S. Shergill, Eromona Whiskey, Madelaine Bridges
article en
1 citations

Abstract

Neutropenia and the more severe, potentially life-threatening agranulocytosis are recognized side effects of clozapine that require regular, mandatory, and life-long blood monitoring. However, most cases of haematological adverse effects occur in the first few months of treatment; therefore, there are now increasing calls for the termination of the mandatory monitoring after this initial period. In this report, we present a patient with treatment-resistant schizophrenia who was successfully treated with clozapine yet developed neutropenia after 9 years. This soon evolved into agranulocytosis requiring the use of granulocyte colony-stimulating factor and eventual clozapine cessation. Such late-onset cases of agranulocytosis are isolated and rare but should not impede the drive to relax mandatory clozapine haematological monitoring, but patients and carers must be aware of potential symptoms of agranulocytosis.

International Clinical PsychopharmacologyVol. 40(6)
Medway School of Pharmacy (GB), King's College London (GB), South London and Maudsley NHS Foundation Trust (GB), Kent and Medway NHS and Social Care Partnership Trust (GB), Kent and Medway Medical School
Openalex Percentile: Top 16%
Blood disorders and treatments
1.82
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Agranulocytosis after long-term clozapine use: a case report — Agostina Secchi, Sukhwinder S. Shergill, et al. · International Clinical Psychopharmacology (2025) | TGRS Research Map | TGRS